Business & Finance
Former Andreessen Horowitz partner Vijay Pande launches concentrated venture firm focused on AI in healthcare
After building a $4 billion biotech practice at a16z, Vijay Pande has co-founded VZVC to make a small number of AI-driven healthcare and clinical trial investments each year.
The short version
- Vijay Pande left his role leading Andreessen Horowitz's $4 billion biotech fund to form VZVC alongside Zach Werner.
- The new firm plans to make roughly five concentrated investments annually and utilizes internal AI tools instead of hiring investment associates.
- VZVC is focusing its strategy on AI applications for healthcare delivery and clinical trials, where high costs and an 80% failure rate persist in traditional drug development.
Key facts
- Vijay Pande co-founded venture firm VZVC with Zach Werner after previously leading Andreessen Horowitz's biotech practice, which grew to manage nearly $4 billion.[TechCrunch]
- VZVC intends to make around five concentrated investments per year rather than dozens, operating without investment associates by using AI agents for day-to-day operations.[TechCrunch]
- Pande stated that the primary areas of focus for VZVC are AI applications in healthcare delivery and clinical trials.[TechCrunch]
- According to Pande, experimental drugs face an 80% failure rate moving from phase one to phase three clinical trials, largely because animal testing models do not reliably predict human outcomes.[TechCrunch]
What remains uncertain
- Whether AI models will successfully reduce the cost and high failure rate of clinical trials remains an ongoing test in the industry.[TechCrunch]
- It is uncertain whether open-source biological foundation models will overcome the proprietary, siloed datasets currently built by individual biotech companies.[TechCrunch]